X. Wang
机构：Harvard University, Alliance for Clinical Trials in Oncology, Zhejiang Cancer Hospital, Cancer Research And Biostatistics
发表论文 6 篇 · 总被引 7 次 · h-index 2
代表论文
- MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies (2026 · Annals of Oncology · 被引 5)
- PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression (2026 · JAMA Oncology · 被引 2)
- Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco (2026 · Clinical Cancer Research)
- CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46) (2026 · Lung Cancer)
- OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer (2026 · Annals of Oncology)
- Determinants of maximally attained level of pulmonary function (2004 · Rivm (National Institute for Public Health and the Environment))